Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neurofibromatosis 1 3Neurofibromatoses 2Neurofibroma 2Vascular Malformations 1Skin Diseases, Vascular 1Neurofibroma, Plexiform 1Melanoma 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Arteriovenous Malformations 1

Interventions

mirdametinib 2tipifarnib 1peginterferon alfa-2b 1binimetinib 1antineoplaston AS 2-1 1antineoplaston A10 1Vincristine 1Temozolomide 1Photochemotherapy 1Mn-PyC3A 1Everolimus 1Celecoxib 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Neurofibroma × mirdametinib × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed
19 enrolled 14 charts
CNS

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡